ArticleMaterials today. Bio2026
Exosomal lncRNA OTUD6B-AS1 as a pathogenic nanocarrier promotes inflammatory macrophage polarization in endometritis via a targetable ceRNA circuit.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometritis, a major inflammatory cause of infertility, is driven by unresolved immune dysregulation in which macrophage polarization is critical. Yet, how inflammatory signaling is spatially propagated within the endometrial microenvironment remains unclear. Here, we report that exosomes-natural nanoscale extracellular vesicles-released from lipopolysaccharide (LPS)-injured endometrial epithelial cells (EECs) act as pathogenic nanocarriers that fuel macrophage-dependent inflammation. We demonstrate that LPS enhances exosome biogenesis and secretion via the AKT/ATG16L1 pathway. These exosomes efficiently deliver their molecular cargo to macrophages, triggering NF-κB activation and polarizing them toward a pro-inflammatory M1 phenotype. RNA sequencing identified lncRNA OTUD6B-AS1 as a highly enriched cargo in exosomes from inflamed EECs. Functional studies established that exosome-mediated transfer of lncRNA OTUD6B-AS1 is both necessary and sufficient to drive M1 polarization. Mechanistically, lncRNA OTUD6B-AS1 functions as a competing endogenous RNA (ceRNA), sequestering miR-128 to relieve its repression on Notch2, thereby amplifying NF-κB signaling. This axis was validated in clinical endometritis tissues, which exhibited elevated lncRNA OTUD6B-AS1 and Notch2 alongside reduced miR-128. Importantly, targeting this pathway-through genetic knockdown of lncRNA OTUD6B-AS1 or pharmacological inhibition of the miR-128/Notch2 node-abolished the pro-inflammatory effects. Our work not only delineates a new exosome-coordinated signaling circuit in endometritis but also highlights exosomes as druggable natural nanoparticles. These findings position exosome-based engineering-such as cargo modulation or designed vesicle delivery-as a promising nanomedicine strategy to intercept pathological cell-cell communication and treat inflammatory diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.